Non-Small Cell Lung

Oncology·MeSH: Neoplasms

Prevalence

75.0 / 100K

Incidence

47.0 / 100K/yr

319 drugs in development·102 companies·1 clinical trial

Drug Pipeline by Phase

Approved(16)

Drug	Company
Alimta®	ELI LILLY & Co (LLY)
Aybintio (SB8)	Organon & Co. (OGN)
Cyramza	ELI LILLY & Co (LLY)
docetaxel	Amneal Pharmaceuticals, Inc. (AMRX)
emrelis	AbbVie Inc. (ABBV)
gavreto	RIGEL PHARMACEUTICALS INC (RIGL)
ibtrozi	Nuvation Bio Inc. (NUVB)
krazati	BRISTOL MYERS SQUIBB CO (BMY)
lorbrena	PFIZER INC (PFE)
opdivo qvantig	BRISTOL MYERS SQUIBB CO (BMY)
paclitaxel	Mylan II B.V. (MYL)
pemetrexed	DR REDDYS LABORATORIES LTD (RDY)
pemfexy	EAGLE PHARMACEUTICALS, INC. (EGRX)
portrazza	ELI LILLY & Co (LLY)
vizimpro	PFIZER INC (PFE)
Zenocutuzumab (Zeno) / BIZENGRI® (zenocutuzumab-zbco)	Merus N.V. (MRUS)

Phase 3(107)

Drug	Company
abp 234	AMGEN INC (AMGN)
aglatimagene besadenovec	Candel Therapeutics, Inc. (CADL)
ak112	Summit Therapeutics Inc. (SMMT)
AK112 Injection	Summit Therapeutics Inc. (SMMT)
Alectinib	Nuvalent, Inc. (NUVL)
amivantamab	GH Research PLC (GHRS)
Amivantamab	Merus N.V. (MRUS)
aumolertinib	EQRx, Inc. (EQRX)
autologous	ASTRAZENECA PLC (AZN)
azacytidine	Merus N.V. (MRUS)
azd0171	ASTRAZENECA PLC (AZN)
azd0240	ASTRAZENECA PLC (AZN)
AZD2936	ASTRAZENECA PLC (AZN)
AZD8205 and AZD5305 and AZD2936	ASTRAZENECA PLC (AZN)
azd9291 80 mg/40 mg	ASTRAZENECA PLC (AZN)
bgb-15025	BeOne Medicines Ltd. (ONC)
BGB-15025	BeOne Medicines Ltd. (ONC)
bgb-a445	BeOne Medicines Ltd. (ONC)
BGB-A445	BeOne Medicines Ltd. (ONC)
BNT116	BioNTech SE (BNTX)
BNT316	BioNTech SE (BNTX)
BNT326	BioNTech SE (BNTX)
BNT327	BioNTech SE (BNTX)
Calderasib	Merck & Co., Inc. (MRK)
CAN-2409	Candel Therapeutics, Inc. (CADL)
canakinumab	Novartis AG (NVS)
Ceralasertib	ASTRAZENECA PLC (AZN)
Cetuximab	ENANTA PHARMACEUTICALS INC (ENTA)
custirsen	ACHIEVE LIFE SCIENCES, INC. (ACHV)
Dato-DXd	ASTRAZENECA PLC (AZN)
datopotamab deruxtecan	ASTRAZENECA PLC (AZN)
Divarasib	ENANTA PHARMACEUTICALS INC (ENTA)
domvanalimab	GILEAD SCIENCES, INC. (GILD)
Domvanalimab	ASTRAZENECA PLC (AZN)
drug	ImmunityBio, Inc. (IBRX)
eftilagimod alfa	IMMUTEP Ltd (PRRUF)
eftilagimod alfa	Immutep Limited (IMMP)
Eftilagimod Alfa	Immutep Limited (IMMP)
Entrectinib	Merus N.V. (MRUS)
Erlotinib	ENANTA PHARMACEUTICALS INC (ENTA)
FOLFIRI	IGM Biosciences, Inc. (IGMS)
FOLFIRI-HD	IGM Biosciences, Inc. (IGMS)
FOLFIRI+cetuximab	IGM Biosciences, Inc. (IGMS)
FOLFOX6/FOLFOX7	IGM Biosciences, Inc. (IGMS)
Four week alternating FOLFOX and FOLFIRI	IGM Biosciences, Inc. (IGMS)
furmonertinib	ArriVent BioPharma, Inc. (AVBP)
HER3-DXd	Merck & Co., Inc. (MRK)
Inavolisib	ENANTA PHARMACEUTICALS INC (ENTA)
Intismeran autogene	Merck & Co., Inc. (MRK)
ivonescimab	Summit Therapeutics Inc. (SMMT)
ivonescimab + ligufalimab	Summit Therapeutics Inc. (SMMT)
Ivonescimab Injection	Summit Therapeutics Inc. (SMMT)
JDQ443	Novartis AG (NVS)
Lazertinib	Merus N.V. (MRUS)
lbl-007	BeOne Medicines Ltd. (ONC)
LBL-007	BeOne Medicines Ltd. (ONC)
Lenvatinib	Merck & Co., Inc. (MRK)
MEDI5752	ASTRAZENECA PLC (AZN)
N-803 + Avelumab	ImmunityBio, Inc. (IBRX)
N-803 + Avelumab + PD-L1 t-haNK	ImmunityBio, Inc. (IBRX)
ociperlimab	BeOne Medicines Ltd. (ONC)
ociperlimab	BeOne Medicines Ltd. (ONC)
olafertinib	Checkpoint Therapeutics, Inc. (CKPT)
Oleclumab	ASTRAZENECA PLC (AZN)
open-label azd9291 80 mg/40 mg	ASTRAZENECA PLC (AZN)
Osimertinib	Merus N.V. (MRUS)
Osimertinib + Savolitinib	ASTRAZENECA PLC (AZN)
osimertinib 80 mg/40 mg	ASTRAZENECA PLC (AZN)
Panitumumab	IGM Biosciences, Inc. (IGMS)
pemetrexed	BeOne Medicines Ltd. (ONC)
pemetrexed	Incyte Corp. (INCY)
pemetrexed	GILEAD SCIENCES, INC. (GILD)
Pemetrexed	Merck & Co., Inc. (MRK)
Pemetrexed	BRISTOL MYERS SQUIBB CO (BMY)
Pemetrexed	ENANTA PHARMACEUTICALS INC (ENTA)
Pemetrexed Disodium	ENANTA PHARMACEUTICALS INC (ENTA)
Pemetrexed Disodium	Merus N.V. (MRUS)
platinum chemotherapy	BridgeBio Oncology Therapeutics, Inc. (BBOT)
platinum-based chemotherapy	ArriVent BioPharma, Inc. (AVBP)
Plinabulin	BeyondSpring Inc. (BYSI)
Pralsetinib	Merus N.V. (MRUS)
Ramucirumab	ASTRAZENECA PLC (AZN)
regn2810/chemo/ipi	REGENERON PHARMACEUTICALS, INC. (REGN)
Rilvegostomig	ASTRAZENECA PLC (AZN)
Rucaparib	Merck & Co., Inc. (MRK)
Sacituzumab tirumotecan	Merck & Co., Inc. (MRK)
Sacituzumab tirumotecan	Merus N.V. (MRUS)
savolitinib	HUTCHMED (China) Limited (HCM)
savolitinib + osimertinib	HUTCHMED (China) Limited (HCM)
sotorasib	REVOLUTION MEDICINES, INC. (RVMD)
Supportive care measures	Merck & Co., Inc. (MRK)
t-dxd	ASTRAZENECA PLC (AZN)
tak-788	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-788	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Taletrectinib	Nuvation Bio Inc. (NUVB)
Telisotuzumab Adizutecan	AbbVie Inc. (ABBV)
Telisotuzumab vedotin	AbbVie Inc. (ABBV)
trametinib	Deciphera Pharmaceuticals, Inc. (DCPH)
tsr-042	TESARO, Inc. (TSRO)
Tyrosine kinase Inhibitors	ENANTA PHARMACEUTICALS INC (ENTA)
uft	ASTRAZENECA PLC (AZN)
V940	Merck & Co., Inc. (MRK)
valacyclovir	Candel Therapeutics, Inc. (CADL)
vinorelbine	ASTRAZENECA PLC (AZN)
Volrustomig	ASTRAZENECA PLC (AZN)
zimberelimab	GILEAD SCIENCES, INC. (GILD)
Zongertinib	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 2(61)

Drug	Company
ABT-869	AbbVie Inc. (ABBV)
ABT-869 .25 mg/kg	AbbVie Inc. (ABBV)
ABT-869 0.10 mg/kg	AbbVie Inc. (ABBV)
Alectinib	Merus N.V. (MRUS)
alk202	SAB BIOTHERAPEUTICS, INC. (SABS)
am0010	ARMO BIOSCIENCES, INC. (ARMO)
amivantamab	ASTRAZENECA PLC (AZN)
BDTX-1535	Black Diamond Therapeutics, Inc. (BDTX)
bnt116	REGENERON PHARMACEUTICALS, INC. (REGN)
canakinumab	Novartis AG (NVS)
capmatinib	Novartis AG (NVS)
capmatinib	Novartis AG (NVS)
Cemiplimab	BioNTech SE (BNTX)
Cobimetinib	Merus N.V. (MRUS)
ct053ptsa	SUNSHINE BIOPHARMA INC. (SBFM)
cylembio	IO Biotech, Inc. (IOBT)
Divarasib	Merus N.V. (MRUS)
env 105	Kairos Pharma, LTD. (KAPA)
EOS-448	iTeos Therapeutics, Inc. (ITOS)
erlotinib	CG Oncology, Inc. (CGON)
fianlimab	REGENERON PHARMACEUTICALS, INC. (REGN)
FOLFOX	ENANTA PHARMACEUTICALS INC (ENTA)
fs118	F-star Therapeutics, Inc. (FSTX)
Immune Checkpoint Inhibitors	ENANTA PHARMACEUTICALS INC (ENTA)
inupadenant	iTeos Therapeutics, Inc. (ITOS)
inupadenant (EOS-850)	iTeos Therapeutics, Inc. (ITOS)
jdq443	Novartis AG (NVS)
Livmoniplimab	AbbVie Inc. (ABBV)
MCLA-129	Merus N.V. (MRUS)
mfolfirinox	BridgeBio Oncology Therapeutics, Inc. (BBOT)
mFOLFOX6	BridgeBio Oncology Therapeutics, Inc. (BBOT)
N-803	CG Oncology, Inc. (CGON)
NALIRIFOX	Merus N.V. (MRUS)
Olaparib	Merus N.V. (MRUS)
Pemetrexed	Merus N.V. (MRUS)
Pemetrexed	iTeos Therapeutics, Inc. (ITOS)
Pemetrexed Disodium for Injection	Merus N.V. (MRUS)
platinum doublet	REGENERON PHARMACEUTICALS, INC. (REGN)
platinum-based doublet	GILEAD SCIENCES, INC. (GILD)
poziotinib	Assertio Holdings, Inc. (ASRT)
quemliclustat	GILEAD SCIENCES, INC. (GILD)
regn7075	REGENERON PHARMACEUTICALS, INC. (REGN)
rmc-4630	REVOLUTION MEDICINES, INC. (RVMD)
RP1	ENANTA PHARMACEUTICALS INC (ENTA)
rtx-224	Rubius Therapeutics, Inc. (RUBY)
rucosopasem manganese	Galera Therapeutics, Inc. (GRTX)
Sapanisertib (CB-228, formerly TAK-228)	Calithera Biosciences, Inc. (CALA)
sarilumab	REGENERON PHARMACEUTICALS, INC. (REGN)
SBRT	Merus N.V. (MRUS)
Serplulimab	Merus N.V. (MRUS)
tislelizumab	Novartis AG (NVS)
tislelizumab	Novartis AG (NVS)
Tremelimumab	ADMA BIOLOGICS, INC. (ADMA)
tusamitamab ravtansine	Sanofi (SNY)
ubamatamab	REGENERON PHARMACEUTICALS, INC. (REGN)
V940	Merus N.V. (MRUS)
Vemurafenib	Merus N.V. (MRUS)
vintafolide	ENDOCYTE INC (ECYT)
vs-7375	Verastem, Inc. (VSTM)
Zelenectide pevedotin	Merus N.V. (MRUS)
zelenectide pevedotin (formerly BT8009)	BICYCLE THERAPEUTICS PLC (BCYC)

Phase 1(75)

Drug	Company
ADCT-601	ADC Therapeutics SA (ADCT)
alk-inhibitor or ret-inhibitor	BioNTech SE (BNTX)
ALT-803	ENANTA PHARMACEUTICALS INC (ENTA)
ALX2004	ALX ONCOLOGY HOLDINGS INC (ALXO)
amivantamab	GH Research PLC (GHRS)
anti-B7-H3 antibody conjugated to topoisomerase I inhibitor	BioNTech SE (BNTX)
anti-HER3 antibody conjugated to topoisomerase I inhibitor	BioNTech SE (BNTX)
apg-1252	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
autologous genetically modified t cells	Adaptimmune Therapeutics PLC (ADAP)
azacytidine	ENANTA PHARMACEUTICALS INC (ENTA)
AZD2936	Merus N.V. (MRUS)
azirkitug	AbbVie Inc. (ABBV)
BBO-10203	BridgeBio Oncology Therapeutics, Inc. (BBOT)
bbo-11818	BridgeBio Oncology Therapeutics, Inc. (BBOT)
BBO-11818	BridgeBio Pharma, Inc. (BBIO)
BBO-11818	ENANTA PHARMACEUTICALS INC (ENTA)
BBO-11818	Merus N.V. (MRUS)
BBO-8520	BridgeBio Oncology Therapeutics, Inc. (BBOT)
bg-60366	BeOne Medicines Ltd. (BEIGF)
bg-60366	BeOne Medicines Ltd. (ONC)
bispecific antibody for pd-l1	BioNTech SE (BNTX)
Bispecific antibody for PD-L1 and VEGF-A	BioNTech SE (BNTX)
Budigalimab	AbbVie Inc. (ABBV)
Cemiplimab	Merck & Co., Inc. (MRK)
cetuximab	BridgeBio Oncology Therapeutics, Inc. (BBOT)
cetuximab	REVOLUTION MEDICINES, INC. (RVMD)
Cetuximab	BridgeBio Pharma, Inc. (BBIO)
Danvatirsen	ASTRAZENECA PLC (AZN)
Danvatirsen	Merus N.V. (MRUS)
daraxonrasib	REVOLUTION MEDICINES, INC. (RVMD)
deltacel	Kiromic Biopharma, Inc. (KRBP)
Digoxin	Merck & Co., Inc. (MRK)
ec1456	ENDOCYTE INC (ECYT)
elvn-002	Enliven Therapeutics, Inc. (ELVN)
enozertinib	Oric Pharmaceuticals, Inc. (ORIC)
Entinostat	Syndax Pharmaceuticals Inc (SNDX)
FOLFOX	BridgeBio Pharma, Inc. (BBIO)
FT836	FATE THERAPEUTICS INC (FATE)
GDC-1971	ENANTA PHARMACEUTICALS INC (ENTA)
GDC-6036	ENANTA PHARMACEUTICALS INC (ENTA)
gen-011	GENOCEA BIOSCIENCES, INC. (GNCA)
H1299 Cell Lysates	CG Oncology, Inc. (CGON)
imgc936	ImmunoGen, Inc. (IMGN)
JANX008	Janux Therapeutics, Inc. (JANX)
ko-2806	Kura Oncology, Inc. (KURA)
MEDI5752	Merus N.V. (MRUS)
Midazolam	Merck & Co., Inc. (MRK)
mobocertinib	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
mobocertinib	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
nalirifox	BridgeBio Oncology Therapeutics, Inc. (BBOT)
NALIRIFOX	ENANTA PHARMACEUTICALS INC (ENTA)
NALIRIFOX	BridgeBio Pharma, Inc. (BBIO)
neo-pv-01	Neon Therapeutics, Inc. (NTGN)
nt-112	ASTRAZENECA PLC (AZN)
nxp900	Nuvectis Pharma, Inc. (NVCT)
Oleclumab	Merus N.V. (MRUS)
osimertinib	Nuvectis Pharma, Inc. (NVCT)
osimertinib	BioNTech SE (BNTX)
Pemetrexed	BridgeBio Pharma, Inc. (BBIO)
Platinum chemotherapy	BridgeBio Pharma, Inc. (BBIO)
ponsegromab	PFIZER INC (PFE)
quaratusugene ozeplasmid	Genprex, Inc. (GNPX)
retifanlimab	Incyte Corp. (INCY)
rmc-5127	REVOLUTION MEDICINES, INC. (RVMD)
rmc-6236	REVOLUTION MEDICINES, INC. (RVMD)
rmc-6291	REVOLUTION MEDICINES, INC. (RVMD)
rmc-9805	REVOLUTION MEDICINES, INC. (RVMD)
Rucaparib	ENANTA PHARMACEUTICALS INC (ENTA)
S241656	IGM Biosciences, Inc. (IGMS)
sar408701	Sanofi (SNY)
sigvotatug vedotin	PFIZER INC (PFE)
tas3351	CG Oncology, Inc. (CGON)
tno155	Novartis AG (NVS)
xmt-2056	Mersana Therapeutics, Inc. (MRSN)
Zidesamtinib	Nuvalent, Inc. (NUVL)

Preclinical(18)

Drug	Company
adxs-503	OLD AYALA, INC (AYLA)
adxs-503	OS Therapies Inc (OSTX)
ast-vac2	ASTERIAS BIOTHERAPEUTICS, INC. (AST)
ATNM-400	Actinium Pharmaceuticals, Inc. (ATNM)
BP1003	BIO-PATH HOLDINGS, INC. (BPTH)
chi3l1 bsabs	Ocean Biomedical, Inc. (OCEA)
chi3l1 mab	Ocean Biomedical, Inc. (OCEA)
EO-1022	Elevation Oncology, Inc. (ELEV)
Fourth-Generation EGFR Inhibitor	Theseus Pharmaceuticals, Inc. (THRX)
fyarro + adagrasib	Whitehawk Therapeutics, Inc. (WHWK)
KRAS program	Cogent Biosciences, Inc. (COGT)
mink-215	MiNK Therapeutics, Inc. (INKT)
oncr-021	Oncorus, Inc. (ONCR)
Pan-mutant BRAF degrader program (proprietary)	Nurix Therapeutics, Inc. (NRIX)
Pan-mutant BRAF program (mutant BRAF degraders)	Nurix Therapeutics, Inc. (NRIX)
THE-349	Theseus Pharmaceuticals, Inc. (THRX)
til	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
ttx-sipdl1	Transcode Therapeutics, Inc. (RNAZ)

Unknown(2)

Drug	Company
ADXS-503	Ayala Pharmaceuticals, Inc. (ADXS)
non-SGLT2 inhibitors	ENANTA PHARMACEUTICALS INC (ENTA)

Early Phase 1(1)

Drug	Company
VTP-600	Barinthus Biotherapeutics plc. (BRNS)

Phase 1/Phase 2(21)

Drug	Company
ABV-1519	ABVC BIOPHARMA, INC. (ABVC)
cetuximab	Novartis AG (NVS)
cetuximab	Novartis AG (NVS)
dzd6008	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
elironrasib	REVOLUTION MEDICINES, INC. (RVMD)
inlexisertib	Deciphera Pharmaceuticals, Inc. (DCPH)
loxo-292	ELI LILLY & Co (LLY)
m1774	GH Research PLC (GHRS)
Neladalkib	Nuvalent, Inc. (NUVL)
opnurasib	NOVARTIS AG (NVSEF)
opnurasib	Novartis AG (NVS)
osimertinib	Genprex, Inc. (GNPX)
osimertinib	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
pemetrexed	REVOLUTION MEDICINES, INC. (RVMD)
platinum-based chemotherapy	Genprex, Inc. (GNPX)
platinum-based chemotherapy	REGENERON PHARMACEUTICALS, INC. (REGN)
platinum-based doublet chemotherapy	REGENERON PHARMACEUTICALS, INC. (REGN)
REC-617	RECURSION PHARMACEUTICALS, INC. (RXRX)
tcr-t library	Alaunos Therapeutics, Inc. (TCRT)
tno155	Novartis AG (NVS)
wsd0922-fu	SUNSHINE BIOPHARMA INC. (SBFM)

Phase 2/Phase 3(7)

Drug	Company
CA-170	CURIS INC (CRIS)
iza-bren	BRISTOL MYERS SQUIBB CO (BMY)
osimertinib	AbbVie Inc. (ABBV)
Pemetrexed	AbbVie Inc. (ABBV)
Pemetrexed	BioNTech SE (BNTX)
screening platform	GH Research PLC (GHRS)
sitravatinib	Mirati Therapeutics, Inc. (MRTX)

Phase 4(11)

Drug	Company
5-FU	Merus N.V. (MRUS)
BMS-986504	BRISTOL MYERS SQUIBB CO (BMY)
Cetuximab	IGM Biosciences, Inc. (IGMS)
Chemotherapy	Merus N.V. (MRUS)
IBI363 + Chemotherapy	Merus N.V. (MRUS)
Monalizumab	ASTRAZENECA PLC (AZN)
osimertinib	ASTRAZENECA PLC (AZN)
Pemetrexed	ASTRAZENECA PLC (AZN)
Relatlimab	BRISTOL MYERS SQUIBB CO (BMY)
trametinib	Novartis AG (NVS)
Trametinib	Novartis AG (NVS)

Compare drugs

Alimta® vs Aybintio (SB8)Alimta® vs Cyramza Alimta® vs docetaxel

Frequently asked questions

How many drugs are in development for Non-Small Cell Lung?

BioSniper tracks 319 drugs in development for Non-Small Cell Lung across 102 companies.

How many clinical trials target Non-Small Cell Lung?

There are 1 clinical trial targeting Non-Small Cell Lung tracked by BioSniper.

What is the prevalence of Non-Small Cell Lung?

The estimated prevalence of Non-Small Cell Lung is approximately 75.0 per 100,000 population.

Deep-dive into Non-Small Cell Lung

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis